In an industry where credibility, compliance and consumer trust are paramount, Heilmittel Group is carving out a unique position as a transatlantic innovator in food supplements. With Bayerische Heilmittel Wissenschaften GmbH (BHW) headquartered in Munich, with a strategic office in Frankfurt, and its Canadian counterpart, North American Heilmittel Inc. (NAH), in Ottawa, the Group bridges European expertise with North American innovation. Two flagship ranges—Cebedi® and Schutz®—are setting new standards in functional nutrition and consumer health. Heilmittel Group has also been recognized as a Company of the Future by Deutsches Innovationsinstitut (diind).
Cebedi®: Ultra-Pure Synthetic CBD with Pharmaceutical-Grade Precision
The Cebedi® brand was born from a simple but ambitious vision: to elevate CBD beyond trend-driven wellness into a scientifically grounded, regulated supplement category. At its core is synthetic CBD, offering unmatched purity, consistency and safety compared to plant-derived alternatives. Manufactured under GMP-certified conditions, Cebedi® ensures pharmaceutical-level quality in every capsule, oil and topical.
Cebedi® stands as one of the few pioneering brands worldwide to achieve recognition as a food supplement, joining a select group of early innovators shaping the regulatory pathway. With approvals in markets such as the UK, Saudi Arabia, UAE and Jordan, it represents a turning point in how cannabinoids are understood and accepted in mainstream nutrition. More and more regulatory bodies globally are embracing this change, acknowledging that synthetic CBD—when developed to pharmaceutical standards—can safely and effectively support consumer wellbeing.
The portfolio includes Cebedi® Oils and Capsules, designed for precise dosing and daily balance, and PuraMouv®, a premium CBD balm, combined with Glucosamine for better joint and muscle relief. With scientific collaborations and growing international reach, Heilmittel Group is demonstrating that cannabinoids, when standardized and responsibly presented, have a rightful place in modern nutrition science.
Schutz®: Drinkable Shots that Protect Health
Alongside Cebedi®, Heilmittel Group’s European R&D team has developed Schutz®, a line of 25 ml functional drinkable shots that reflect Germany’s tradition of scientific rigor and elegant design. The name—meaning “protection” in German—encapsulates the brand’s mission: to safeguard wellbeing across life stages and lifestyles.
The range includes six targeted formulations:
• CalmezZolli® – natural sleep and stress relief
• Obelisko Vitalis® – energy and mental performance
• FocuThory® – dual day/night support for children and adolescents with ADHD
• RespiVelle® – immunity and respiratory health, including asthma and COPD support
• SerNée® – pregnancy and postpartum wellness
• CranVie® – urinary tract health powered by cranberry extract
Unlike generic liquid supplements, Schutz® shots are designed as clinically inspired, single-use daily solutions, combining bioavailable actives with strict EU compliance. Standardized bilingual packaging—German and English— reinforces its export-ready positioning.
Together, Cebedi® and Schutz® represent two pioneering pathways to the future of consumer health: one anchored in synthetic CBD science, the other in precision-targeted micronutrition. Both are supported by GMP-certified manufacturing across Germany, Spain and Switzerland and rigorous adherence to international food supplement regulations.
As regulators worldwide increasingly embrace CBD’s reclassification and consumers demand smarter, safer and more effective nutrition, Heilmittel Group is meeting these needs head-on. Cebedi® and Schutz® are not just product ranges; they are next-generation food supplement solutions designed to protect health, restore balance and empower modern lifestyles.
Cebedi and Schutz are registered trademarks of BHW Bayerische Heilmittel Wissenschaften GmbH (Germany) and NAH - North American Heilmittel Inc. (Canada).
Headquarters :
. ManagementThank you for Subscribing to Food Business Review Weekly Brief
